Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
J Matern Fetal Neonatal Med ; 35(25): 5308-5311, 2022 Dec.
Article in English | MEDLINE | ID: mdl-33504230

ABSTRACT

BACKGROUND: The optimal gestational age at delivery for stable women with suspected placenta accreta is still subject of debate. OBJECTIVE: To estimate the likelihood of vaginal bleeding necessitating expedited delivery in women with placenta accreta according to gestational age at planned cesarean hysterectomy. STUDY DESIGN: This was a multicenter cohort study. Singleton pregnancies at risk of placenta accreta because of placenta previa in the setting of prior cesarean delivery were included. Outcomes were compared in cohort of women who had planned cesarean hysterectomy at 34 0/7 - 34 6/7 weeks versus at 35 0/7 - 35 6/7 weeks. The primary outcome was incidence of vaginal bleeding severe enough to necessitate delivery. RESULTS: 118 singleton pregnancies with placenta previa in the setting of prior cesarean delivery, and confirmed placenta accreta at the time of delivery were included in the study. Women who had planned cesarean hysterectomy at 34 weeks had lower episodes of vaginal bleeding severe enough to necessitate immediate or emergency delivery (20.6% vs 38.0%; odds ratio (OR) 0.42, 95% confidence interval (CI) 0.19 to 0.96). Eight women (11.8%) in the 34 weeks group and 6 women (12.0%) in the 35 weeks group delivered before the planned date due to onset of spontaneous labor (OR 0.98, 95% CI 0.32 to 3.02). CONCLUSION: In singleton gestations with suspected placenta accreta, planned cesarean hysterectomy at 34 0/7 - 34 6/7 weeks was associated with a decreased chance of unscheduled delivery due to severe vaginal bleeding. CONDENSATION: In case of placenta accreta, planned cesarean hysterectomy at 34 weeks was associated with decreased chance of unscheduled delivery due to severe vaginal bleeding.


Subject(s)
Placenta Accreta , Placenta Previa , Pregnancy , Female , Humans , Placenta Accreta/epidemiology , Placenta Accreta/surgery , Placenta Previa/epidemiology , Placenta Previa/surgery , Gestational Age , Cohort Studies , Retrospective Studies , Uterine Hemorrhage/epidemiology , Hysterectomy
2.
Eur J Obstet Gynecol Reprod Biol ; 144(1): 44-7, 2009 May.
Article in English | MEDLINE | ID: mdl-19297072

ABSTRACT

OBJECTIVE: To evaluate if pre-operative GnRH-a modify uterine leiomyoma pseudocapsule and the possible clinical effects of these changes. STUDY DESIGN: The study was performed at the University Federico II of Naples on 33 premenopausal patients submitted to laparotomic myomectomy after treatment with triptorelin depot. 29 untreated patients formed the control group. The operating time, the intraoperative bleeding and the prompt identification of the cleavage plan between myoma and myometrium were evaluated. The pseudocapsule features and the immunoexpression of PCNA and CD34 in this area were studied. RESULTS: Treated patients showed lower blood loss and not clearly identifiable cleavage plan, but without any significant increase in the operating time. Treated lesions showed less evident border between myoma and myometrium and lower PCNA and CD34 pseudocapsule immunoexpression than untreated ones. CONCLUSION: We propose the changes of leiomyoma pseudocapsule as partial explanations of the reported clinical and surgical findings after pre-operative GnRH-a.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Gonadotropin-Releasing Hormone/agonists , Leiomyoma/drug therapy , Leiomyoma/surgery , Preoperative Care/methods , Triptorelin Pamoate/therapeutic use , Uterine Neoplasms/drug therapy , Uterine Neoplasms/surgery , Adult , Antigens, CD34/metabolism , Antineoplastic Agents, Hormonal/pharmacology , Blood Loss, Surgical/prevention & control , Cell Proliferation/drug effects , Delayed-Action Preparations , Female , Humans , Leiomyoma/blood supply , Myometrium/metabolism , Myometrium/pathology , Myometrium/surgery , Neovascularization, Pathologic/drug therapy , Proliferating Cell Nuclear Antigen/metabolism , Triptorelin Pamoate/pharmacology , Uterine Neoplasms/blood supply
SELECTION OF CITATIONS
SEARCH DETAIL